The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/5/2019 |
Start Date: | November 28, 2018 |
End Date: | January 12, 2022 |
Contact: | Boehringer Ingelheim |
Email: | clintriage.rdg@boehringer-ingelheim.com |
Phone: | 1-800-243-0127 |
XENERA™-1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Post-menopausal Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
The main objective of the trial is to assess the anti-tumor activity of xentuzumab in
combination with everolimus and exemestane over everolimus and exemestane in post menopausal
patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
combination with everolimus and exemestane over everolimus and exemestane in post menopausal
patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
Inclusion Criteria:
- Documented histologically confirmed breast cancer with ERand/ or PgR-positive and
HER2-negative status
- Locally advanced or metastatic breast cancer not deemed amenable to curative surgery
or curative radiation therapy
- Archival tumour sample available at the time of informed consent and provided to the
central laboratory around the time of randomisation. Patients must provide a
formalin-fixed paraffin embedded (FFPE) tissue biopsy sample preferably taken at the
time of presentation with recurrent or metastatic disease (provision of a biopsy
sample taken from the bone is not acceptable).
- Patients must satisfy the following criteria for prior therapy:
- Progressed during treatment or within 12 months of completion of adjuvant therapy
with an aromatase inhibitor and/or tamoxifen if post-menopausal, or tamoxifen if
pre or peri-menopausal or
- Progressed while on or within 1 month after the end of prior aromatase inhibitor
therapy for advanced/metastatic breast cancer if post-menopausal, or prior
endocrine treatment for advanced/metastatic breast cancer if pre- or
peri-menopausal.
- Patients must not have received more than one previous line of non-steroidal aromatase
inhibitor treatment for advanced/metastatic disease. Prior treatment with one line of
CDK4/6 inhibitors is allowed.
- Prior treatment with fulvestrant if duration was at least 2 years in the adjuvant
setting or at least 6 months in the metastatic setting is allowed.
- Patients must be post-menopausal at time of signature of trial informed consent.
- Patients must have
- At least one measurable non-visceral lesion according to RECIST version 1.1 in
either lymph nodes, soft tissue, skin and/or
- At least one measurable non-visceral lesion according to RECIST version 1.1 as
lytic or mixed (lytic + blastic) in bone and/or
- At least one non-measurable lytic or mixed (lytic + blastic) bone lesion
according to RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
- Adequate organ function
Exclusion Criteria:
- Previous treatment with agents targeting the IGF pathway, PI3K, AKT, or mTOR pathways
- Prior treatment with exemestane (except adjuvant exemestane stopped >12 months prior
to start of study treatment as long as the patient did not recur during or within 12
months after the end of adjuvant exemestane)
- Evidence of visceral metastasis/es (i.e. liver, lung, peritoneal, pleural metastases,
malignant pleural effusions, malignant peritoneal effusions)
- History or evidence of metastatic disease to the brain
- Leptomeningeal carcinomatosis
- Any previous chemotherapy for HR+ HER2- metastatic breast cancer
- Radiotherapy within 4 weeks prior to the start of study treatment
- Use of concomitant systemic sex hormone therapy
- History or presence of cardiovascular abnormalities
- Known pre-existing interstitial lung disease
- Further exclusion criteria apply
We found this trial at
11
sites
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3840 Broadway
Fort Myers, Florida 33901
Fort Myers, Florida 33901
(239) 275-6400
![Florida Cancer Specialists](/wp-content/uploads/logos/florida-cancer-specialists.jpg)
Phone: +001 (239) 940-6890
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Goodyear, Arizona 85338
Phone: +001 (623) 207 3000
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
Nashville, Tennessee 37023
615-320-5090
![Tennessee Oncology, PLLC](/wp-content/uploads/logos/tennessee-oncology-pllc.jpg)
Phone: +001 (615) 329-7274
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Philadelphia, Pennsylvania 19124
Phone: +001 (215) 537 7400
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)